Skip to main content

Table 2 Frequency of fractures among ADT users and nonusers

From: Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand

 

Any fractures (N = 1538)

Hip fractures (N = 338)

Vertebral fractures (N = 273)

No ADT (n = 16,167)

524 (3.2 %)

120 (0.7 %)

136 (0.8 %)

Any ADT (n = 9377)

1014 (10.8 %)

218 (2.3 %)

137 (1.5 %)

  GnRH agonists + Anti-androgens

611 (60.3 %)

110 (50.5 %)

72 (52.6 %)

        GnRH agonist only

130 (12.8 %)

43 (19.7 %)

25 (18.2 %)

        Anti-androgen only

147 (14.5 %)

43 (19.7 %)

22 (16.0 %)

        Orchiectomy alone

38 (3.7 %)

10 (4.6 %)

9 (6.6 %)

 Orchiectomy + pharmacologic ADT

88 (8.7 %)

12 (5.5 %)

9 (6.6 %)

  1. ADT androgen deprivation therapy, GnRH gonadotropin-releasing hormone